Oral version of simelglutide approved for marketing in China, clinical results show that it can effectively lower sugar and lose weight.
2024/03/14 14:31
Oral version of simelglutide approved for marketing in China, clinical results show that it can effectively lower sugar and lose weight.
On January 26, 2024, the official website of the State Drug Administration (SDA) showed that Simeglutide tablets developed by Novo Nordisk were approved for marketing for the treatment of type 2 diabetes. This is also the first oral GLP-1 receptor agonist approved for marketing in China. Previously, the injectable version of simelglutide was approved for marketing in China in 2021, also for the treatment of type 2 diabetes.2023 On March 24, 2023, Novo Nordisk released the oral version of simelglutide in the treatment of type 2 diabetes.
